

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

09/910059
WIPO

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C12N 15/62, 15/13, C07K 16/30, 16/46, A61K 47/48, C07K 19/00, 14/705, C12N 9/64, 5/10, 1/21, 5/20 // A01K 67/027, A01H 1/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/42329 (43) International Publication Date: 13 November 1997 (13.11.97)</p>
<p>(21) International Application Number: PCT/GB97/01165 (22) International Filing Date: 29 April 1997 (29.04.97) (30) Priority Data: 9609405.7 4 May 1996 (04.05.96) GB 9703103.3 14 February 1997 (14.02.97) GB (71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): COPLEY, Clive, Gra- ham [GB/GB]; Zeneca Pharmaceuticals, Mereside, Alder- ley Park, Macclesfield, Cheshire SK10 4TG (GB). EDGE, Michael, Derek [GB/GB]; Zeneca Pharmaceuticals, Mere- side, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). EMERY, Stephen, Charles [GB/GB]; Zeneca Pharma- ceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p>		<p>(74) Agent: GILES, Allen, Frank; Zeneca Pharmaceuticals, Intellec- tual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM</p> <p>(57) Abstract</p> <p>The invention relates to an anti-CEA monoclonal antibody (named "806.077 antibody") of murine origin and useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions (CDRs) have the following sequences: heavy chain; CDR1 DNYMH, CDR2 WIDPENGDT EYAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. Humanised antibodies are described. The antibody is preferably in the form of a conjugate with either an enzyme suitable for use in an ADEPT system, especially a carboxypeptidase, or with a co-stimulatory molecule such as the extracellular domain of human B7.1.</p>		